“…A decade later the first ribavirin-resistant mutants of poliovirus selected in the laboratory (Pfeiffer and Kirkegaard, 2003), and of HCV from patients under ribavirin monotherapy were described (Young et al, 2003). Subsequent work has characterized viral mutants resistant to mutagenic agents, particularly ribavirin, FU, and 5-AZA-C (Pfeiffer and Kirkegaard, 2005b;Sierra et al, 2007;Arias et al, 2008;Agudo et al, 2010;Levi et al, 2010;Arribas et al, 2011;Feigelstock et al, 2011;Domingo-Calap et al, 2012;Sadeghipour et al, 2013;Zeng et al, 2013Zeng et al, , 2014; among other studies). The major overall conclusion of these investigations is that viruses can develop resistance to mutagenic nucleotide analogs as they do to nonmutagenic inhibitors.…”